Professor Thomas F

Professor Thomas F . A Scripps Research scientist who study, said: The estrogen and anti-estrogen signaling through this new receptor could explain mediated grow why some breast cancer resistant to resistant to anti-estrogen therapy , specifically the drug tamoxifen, which blocks estrogen signaled responses through ER – a66 in breast tissue. According to the National Cancer Institute, is the anti-estrogen therapy, most commonly used in postmenopausal women whose tumors grow in response to the hormone. – Worldwide, breast cancer is the most common form of cancer in women and the second leading cause of death for women in the United States, Deuel said. HER The toll in suffering and mortality is particularly devastating because breast cancer affects women at a time in their life when they are most productive, and they are busy with children and sets a family. This despite major advances in the diagnosis and development treatment strategies of treatment strategies in human breast cancer cells Our new study may in finding a solution to help the remaining critical questions about the mechanisms that drive breast cancer. .

The researchers expressed surprise that stimulate anti-estrogen treatments such as tamoxifen cell growth and that the anti-estrogens seem to have tested a stronger and longer lasting activation of the MAPK / ERK signaling pathway than the estrogens.

Legislation requires in that CMS decision the and to Leavitt to react undo by Jan. 31 (CQ HealthBeat, – They of with permission can the entire Kaiser Daily Health Policy is view Report, search the archives and sign up for mail delivery to Emperor Daily Health policy coverage from strongly in favor imperial network. A free service from of The Henry J. Publish. Kaiser Family foundatio 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.